Skip to main content
SpringerLink
Log in

HDT with PBSCT cost effective in non-Hodgkin's lymphoma?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau J-L, Woronoff-Lemsi M-C, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-hodgkin's lymphoma. PharmacoEconomics 27: 55-68, No. 1, Jan 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

HDT with PBSCT cost effective in non-Hodgkin's lymphoma?. Pharmacoecon. Outcomes News 574, 8 (2009). https://doi.org/10.2165/00151234-200905740-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905740-00017

Keywords

Search

Navigation